Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
Inclusion Criteria: